secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-09-04T21:00:39+00:00
Accession:  0001140361-26-035802
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis partner Novartis: pelacarsen Phase 3 Lp(a)HORIZON misses primary CV endpoint
--------------------------------------------------------------------------------

- Pelacarsen Phase 3 Lp(a)HORIZON did not meet primary endpoint of reducing CV events vs placebo (CV death, non-fatal MI/stroke, urgent revascularization).
- Substantially lower Lp(a) levels achieved consistent with prior studies; acceptable safety profile; full data at upcoming medical congress.
- Ionis discovered pelacarsen; Novartis licensed rights in Feb 2019; CEO Monia says results inform future cardiovascular care.
- Ionis continues independent commercialization of TRYNGOLZA, DAWNZERA, ZANVASTRO; pipeline otherwise unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126035802/0001140361-26-035802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126035802/ef20081690_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer